89bio, Inc. Proceeds from Warrant Exercises
89bio, Inc. reported Proceeds from Warrant Exercises of $0 for the 6-month period ending 2025-06-30, per its 10-Q filed 2025-08-08.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromWarrantExercises · last filed 2025-08-08
- 89bio, Inc. proceeds from warrant exercises for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- 89bio, Inc. proceeds from warrant exercises for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- 89bio, Inc. proceeds from warrant exercises for the quarter ending 2024-12-31 was $0.00.
- 89bio, Inc. proceeds from warrant exercises for the quarter ending 2024-09-30 was $24.66M.
- 89bio, Inc. proceeds from warrant exercises for fiscal 2024 was $54.21M, a 247.70% increase from fiscal 2023.
- 89bio, Inc. proceeds from warrant exercises for fiscal 2023 was $15.59M, a 1340.85% increase from fiscal 2022.
- 89bio, Inc. proceeds from warrant exercises for fiscal 2022 was $1.08M.
| Period end | Proceeds from Warrant Exercises 3 month | Proceeds from Warrant Exercises 6 month | Proceeds from Warrant Exercises 9 month | Proceeds from Warrant Exercises 12 month |
|---|---|---|---|---|
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $0.00 10-Q · filed 2025-08-08 | $0.00 derived: sum of 3 quarters · filed 2025-08-08 | $24.66M derived: sum of 4 quarters · filed 2025-08-08 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-02 | $0.00 derived: sum of 2 quarters · filed 2025-05-02 | $24.66M derived: sum of 3 quarters · filed 2025-05-02 | $52.41M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $24.66M derived: sum of 2 quarters · filed 2025-02-27 | $52.41M derived: sum of 3 quarters · filed 2025-08-08 | $54.21M 10-K · filed 2025-02-27 |
| 2024-09-30 | $24.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $52.41M derived: sum of 2 quarters · filed 2025-08-08 | $54.21M 10-Q · filed 2024-11-07 | $54.21M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-06-30 | $27.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $29.54M 10-Q · filed 2025-08-08 | $29.54M derived: sum of 3 quarters · filed 2025-08-08 | $29.54M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $1.80M 10-Q · filed 2025-05-02 | $1.80M derived: sum of 2 quarters · filed 2025-05-02 | $1.80M derived: sum of 3 quarters · filed 2025-05-02 | $8.43M derived: sum of 4 quarters · filed 2025-05-02 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $0.00 derived: sum of 2 quarters · filed 2025-02-27 | $6.63M derived: sum of 3 quarters · filed 2025-02-27 | $15.59M 10-K · filed 2025-02-27 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $6.63M derived: sum of 2 quarters · filed 2024-11-07 | $15.59M 10-Q · filed 2024-11-07 | $16.62M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $6.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $15.59M 10-Q · filed 2024-08-05 | $16.62M derived: sum of 3 quarters · filed 2025-02-27 | |
| 2023-03-31 | $8.96M 10-Q · filed 2024-05-09 | $9.99M derived: sum of 2 quarters · filed 2025-02-27 | ||
| 2022-12-31 | $1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $1.08M 10-K · filed 2025-02-27 | ||
| 2022-09-30 | $53.00K 10-Q · filed 2023-11-09 |